FDA Shortages Task Force Looks More Broadly To Tackle Root Causes
Executive Summary
FDA’s latest drug shortages task force aims to encourage investment in the reliable manufacture of generic sterile injectables that are fundamental to the practice of medicine. While the agency’s first task force continues to work with industry to avert shortages, the second will strike at underlying structural issues that cause persistent shortages of these critical medicines.
You may also be interested in...
Lauren Silvis To Depart US FDA, Adding To High-Level String Of Agency Turnover In 2019
Lauren Silvis will leave her post as chief of staff at the US FDA in the next several weeks, when she will be replaced by associate commissioner for strategic initiatives and external affairs Keagan Lenihan.
Drug Shortages: Is "Buy American" One Solution?
Moving more manufacturing to the US could help increase supply chain reliability, which could prevent or blunt shortages, an industry representative argues.
Drug Shortages: Is "Buy American" One Solution?
Moving more manufacturing to the US could help increase supply chain reliability, which could prevent or blunt shortages, an industry representative argues.